RIO DE JANEIRO, BRAZIL – The pioneering of Brazilian psychedelic science has marked a new finding. After performing the first controlled clinical trial with this class of substances (ayahuasca, in this case) against depression, Northeast researchers show that the progress seems to stem from a regression in the inflammatory reaction.
The theory linking this mental disorder with inflammation, a typical immune system response to attack by external agents such as viruses, has not yet been proven. Nor is it known what triggers mild inflammation in depressed patients, only that they have altered levels of compounds, such as cortisol, which play a . . .